Max Financial Services Ltd has issued an Investor Release for Q2 FY24, stating that pursuant to the approval of the MFSL and Max Life Boards and subject to regulatory approvals, Axis Bank will be infusing Rs 1,612 Cr by subscribing to 14.26 Cr equity shares of Max Life, at fair market value ~ Rs 113.06 per share (determined basis DCF methodology). This capital infusion will help Max Life to support its future growth ambitions, augment its capital position, and improve solvency margins.